DCK antibody (AA 181-260)
Quick Overview for DCK antibody (AA 181-260) (ABIN714176)
Target
See all DCK AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 181-260
-
Predicted Reactivity
- Human,Mouse,Rat,Pig,Horse
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human DCK
-
Isotype
- IgG
-
-
-
-
Application Notes
-
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
Expiry Date
- 12 months
-
-
- DCK (Deoxycytidine Kinase (DCK))
-
Alternative Name
- DCK
-
Background
-
Synonyms: DCK, dCK, DCK protein, DCK_HUMAN, Deoxycytidine kinase, EC 2.7.1, EC 2.7.1.74, MGC117410, MGC138632, OTTHUMP00000219118, OTTHUMP00000219119.
Background: Deoxycytidine kinase is responsible for the phosphorylation of several deoxyribonucleosides and their analogs. Deficiency of this enzyme activity is associated with resistance to antiviral and anticancer chemotherapeutic agents, whereas increased enzyme activity is associated with increased activation of these compounds to cytotoxic nucleoside triphosphate derivatives. It is the rate limiting enzyme in the activation of many important anticancer and retroviral drugs and its activity is often decreased in cells that are resistant to cytosine arabinoside.
-
Gene ID
- 1633
Target
-